Flexibility and efficiency with Tecan Integration Group

 

 

 

 

 
 

 

 

 

 

 

 

Siena Biotech, an innovative drug discovery company in Italy, has chosen four highly tailored Tecan Freedom EVO® workstations for different roles in drug development. Built by the Tecan Integration Group (TIG), each system has been invaluable in increasing throughput and accuracy in testing compounds as potential therapeutic drugs. Marta Gherardi from the Compound Management Group explained: “We chose our Freedom EVO systems to improve throughput, customized to exactly meet our needs by TIG. We visited TIG and looked at all the possibilities for customization, choosing the ones that best suited us. The instruments were then built in Switzerland before being integrated with our other systems on-site.”

 

Federico Cappelli from the Biomolecular Screening Group added: “We are still at the early stages of setting up some of the different applications on our Freedom EVO system, and we are currently working on automating our Madin-Darby canine kidney (MDCK) cell line permeability assays in collaboration with the Met Profiling Group. The flexibility of the system will allow us to reproduce the results already obtained by a dedicated operator, increase the throughput and minimize inter-operator variability.”
 
To find out more on Tecan Integration Group, visit www.tecan.com/tig

 

 

 

For more information about Tecan, please contact:

 

 

 

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. With its subsidiary REMP (www.remp.com), Tecan is the market leader in automated laboratory storage and logistics systems. Its clients include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2008, Tecan generated sales of CHF 396 million (USD 366.7 million; EUR 250.7 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).